TY - JOUR
T1 - Molecular diagnostics in dermatology
T2 - An online survey to study usage, obstacles and requirements in Germany
AU - Tizek, Linda
AU - Schuster, Barbara
AU - Gebhardt, Christoffer
AU - Reich, Kristian
AU - von Kiedrowski, Ralph
AU - Biedermann, Tilo
AU - Eyerich, Kilian
AU - Zink, Alexander
AU - Garzorz-Stark, Natalie
N1 - Publisher Copyright:
© 2021 The Authors. Journal der Deutschen Dermatologischen Gesellschaft published by John Wiley & Sons Ltd on behalf of Deutsche Dermatologische Gesellschaft.
PY - 2022/3
Y1 - 2022/3
N2 - Background and objectives: Molecular diagnostics (MDx) increasingly gains importance in dermatology and its application is a prerequisite for personalized medicine. The goal of this cross-sectional study was to determine how MDx is implemented in dermatologists’ offices in the three fields of oncology, inflammation and infectiology and which hurdles office-based dermatologists face in terms of MDx. Methods: Physician members of the Association of the German Dermatologists (Berufsverband der Deutschen Dermatologen e. V.; BVDD) were surveyed via an online questionnaire on MDx. Results: 39.6 % of the 192 participants reported using MDx. Of these, the vast majority used MDx for diagnosing infectious diseases (86.5 % and 44.3 % of users perform MDx for detection of funghi and sexually transmitted diseases, respectively). Only a small minority applied MDx to answer oncological or immunological questions. The major obstacles for non-users as compared to users were difficulties in implementation, lack of expertise as well as time, personnel, and technical availability. Reimbursement was a main issue in both groups. Conclusions: Despite availability of specific therapies requiring precision medicine, MDx has not yet been broadly implemented in office-based dermatology. To advance MDx, more needs to be done in terms of continuous education, availability of reliable and valid tests, and reimbursability.
AB - Background and objectives: Molecular diagnostics (MDx) increasingly gains importance in dermatology and its application is a prerequisite for personalized medicine. The goal of this cross-sectional study was to determine how MDx is implemented in dermatologists’ offices in the three fields of oncology, inflammation and infectiology and which hurdles office-based dermatologists face in terms of MDx. Methods: Physician members of the Association of the German Dermatologists (Berufsverband der Deutschen Dermatologen e. V.; BVDD) were surveyed via an online questionnaire on MDx. Results: 39.6 % of the 192 participants reported using MDx. Of these, the vast majority used MDx for diagnosing infectious diseases (86.5 % and 44.3 % of users perform MDx for detection of funghi and sexually transmitted diseases, respectively). Only a small minority applied MDx to answer oncological or immunological questions. The major obstacles for non-users as compared to users were difficulties in implementation, lack of expertise as well as time, personnel, and technical availability. Reimbursement was a main issue in both groups. Conclusions: Despite availability of specific therapies requiring precision medicine, MDx has not yet been broadly implemented in office-based dermatology. To advance MDx, more needs to be done in terms of continuous education, availability of reliable and valid tests, and reimbursability.
UR - http://www.scopus.com/inward/record.url?scp=85122007594&partnerID=8YFLogxK
U2 - 10.1111/ddg.14659
DO - 10.1111/ddg.14659
M3 - Article
C2 - 34962069
AN - SCOPUS:85122007594
SN - 1610-0379
VL - 20
SP - 287
EP - 295
JO - JDDG - Journal of the German Society of Dermatology
JF - JDDG - Journal of the German Society of Dermatology
IS - 3
ER -